Trial Profile
Effect of switching to raltegravir and/or adding losartan on the inflammatory/immune-activation mediators in treated HIV patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Apr 2018
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Losartan
- Indications HIV-1 infections
- Focus Biomarker; Pharmacodynamics
- 19 Apr 2018 New trial record
- 07 Mar 2018 Results presented at the 25th Conference on Retroviruses and Opportunistic Infections